5/21/2014 10:45 PM ET|
3 dividend stocks for a rocky summer
In a market like this, boring is beautiful. These shares have kept pace with or beaten the broader market this year but remain overlooked.
It's been a choppy stock market so far in 2014, particularly for the "risk on" momentum shares that were last year's leaders.
Popular biotechs such as Vertex (VRTX) are off by double digits. Tech mainstay Amazon (AMZN) is down about 24 percent. And recent cult stocks Twitter (TWTR) and 3D Systems (DDD) have been cut in half this year.
Of course, it's not all gloomy. The broader S&P 500 ($INX) has slowly plodded about 2 percent higher in the face of these troubles.
And some stocks have pushed even higher. Surprisingly, they are some of the sleepiest names on Wall Street -- defensive blue-chip dividend payers that were largely overlooked during the market's roaring run of 2013.
And as the market gets more selective and investors increasingly move "risk off," these picks could continue to do very well across the rest of 2014. Here they are:
Longtime readers of my column (hello to all three of you!) will know that one of my favorite long-term investing trends is the demographic shift in America that is taking place. As baby boomers age, it will transform many industries, particularly across health care.
A great way to play this trend is via high-yield real estate investment trusts that focus on elder care. A company like Ventas (VTR) is a perfect example, since it controls some 700 senior-housing facilities, 400 skilled-nursing facilities and 250 medical-office buildings across the U.S.
Of course, this demographics trade hadn't really borne any fruit across 2011 and 2012 as health-care REITs remained stuck in neutral, but the risk-off environment and a hunger for yield amid falling Treasury interest rates has re-energized interest in stocks like Ventas.
But short-term stock performance aside, the dividend is what should keep you interested in Ventas long term. Even after a 16 percent run-up, the stock yields 4.4 percent. The company has increased its distributions 120 percent in the past 10 years, from 32.5 cents per share in 2004 to 72.5 cents today.
Ventas is also gobbling up smaller competitors, with eight major acquisitions over the past decade that total over $16 billion, in order to ensure future growth. These are also high-quality purchases, with so-called triple-net leases that mean tenants, not Ventas, are obligated to pay for any property-related expenses like taxes, maintenance and insurance.
Given the recent tailwind in a risk-off environment, Ventas could perform well for the rest of the year. And given its long-term dividend potential, investors should have confidence that this REIT is not just a swing trade but a legitimate holding for many years to come.
2. Johnson & Johnson
Johnson & Johnson (JNJ) is an old favorite among defensive dividend stocks. It's a health-care play -- but also a consumer-staples play, thanks to popular brands including Band-Aid, Tylenol and Splenda.
The health-care angle makes the stock, JNJ, pretty recession-proof, since medical expenses don't go away even in tough times, and the company's consumer-brand power gives it stability for the long run.
Many investors have been overlooking Johnson & Johnson after the company struggled from 2010 to 2012 amid quality-control issues and big product recalls. However, since CEO Alex Gorxy took over two years ago, the company has been marching steadily higher. The stock is up almost 60 percent since Gorsky took over vs. 35 percent or so for the S&P 500 ($INX). That includes an impressive gain of 10 percent this year despite a pretty flat market.
And, long term, J&J has a total return of about 140 percent including dividends over the past 10 years, thanks to distributions that have increased 145 percent from 28.5 cents per share each quarter in 2004 to 70 cents today (for a 2.8 percent yield).
While naysayers may point out that Johnson & Johnson could be overvalued after this run, it's still trading for about 15.5 times future earnings -- which is exactly the forward P/E of the broader market right now.
I have confidence that J&J will hang tough even if things get increasingly volatile in 2014. But more importantly, I'd have confidence in buying shares for a long-term, dividend-oriented portfolio right now.
Intel (INTC) is another stock like Johnson & Johnson that has largely been overlooked for the past few years. But those who haven't been paying attention for some time may have missed out on the recent strength in this chip maker.
Sure, the mobile revolution is severely limiting the growth potential for Intel, and revenue has been stagnant since 2011. However, despite a continuation of top-line issues in the first quarter, there are signs that Intel is much better off than some naysayers believe.
Intel beat expectations in the first three months of the year, thanks in part to its data-center business and (surprise!) corporate PC sales.
The strong outlook for corporate sales resulted in a number of analyst moves on Intel, including an upgrade to "buy" at Deutsche Bank with a $30 target. Separately, Pacific Crest and Jefferies each reiterated bullish calls with $32 and $35 targets, respectively.
I remain convinced that the poor performance of enterprise tech over the past few years will start to change as businesses begin to invest again. And if that trend proves true, we could see Intel continue to see growth in its data center and PC business in the short term.
Long term, Intel continues to make progress on mobile chip sets and adapting its business to a new environment. Beyond the strategy, there's the juicy 3.4 percent dividend and a strong history of increases. Intel's dividends have advanced 450 percent in the past 10 years, from 4 cents quarterly to 22 cents, but are still comfortably below half of projected earnings.
And with $30 billion in cash and investments on the books, and over $20 billion in annual operating cash flow, there's a reasonable expectation of continued dividend growth going forward.
More from MarketWatch
VIDEO ON MSN MONEY
I have HCP and if I add to my REIT position I'll probably add VTR. If I didn't have Abbott Labs, I'd have Johnson & Johnson.
I'm not currently invested in tech stocks beyond Emerson Electric, but may invest in CSCO, QCOM, or INTC. INTC has a couple consecutive years of decreased sales and earnings, but has a durable competitive advantage. Its projected to grow earnings by 7.5% per year for the next 5 years. While projections by "experts" often leave much to be desired, they are relatively accurate for long-established, slow-growth, sector leaders like INTC. Add in the 3.4% dividend and the P/E of 14 looks very attractive.
Personally, I'm invested in HCP (HCP), the largest of the healthcare REITs, which has increased its dividend every year for 28 straight years, recovered quickly from the 2008-9 crash (many REITs still haven't recovered), and at 5.2% yield, is the highest dividend payer of the S&P Dividend Aristocrats.
But VTR's distribution of healthcare properties is different than HCP, it's very well managed and it's financials look great, and if I add to my position I'm probably going to do it with VTR instead of putting more in HCP in order to hedge my bet a little - both should prosper as Baby Boomers age.
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
[BRIEFING.COM] The major averages ended the midweek session with slim gains after showing some intraday volatility in reaction to the release of the latest policy directive from the Federal Open Market Committee. The S&P 500 added 0.1%, while the relative strength among small caps sent the Russell 2000 higher by 0.3%.
Equities spent the first half of the session near their flat lines as participants stuck to the sidelines ahead of the FOMC statement, which conveyed no changes to the ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|